Aligos Therapeutics, Inc. (ALGS) Financials

ALGS Assets vs Liabilities

DateAssetsLiabilities
2023-12-31 153.9 million 61.8 million
2023-09-30 85.9 million 31.0 million
2023-06-30 106.1 million 36.5 million
2023-03-31 121.7 million 37.0 million

ALGS Free Cash Flow and Stock based compensation

Graph available only for supporters. Become a supporter to see it.
DateFree Cash FlowStock based compensation
2023-12-31 -22.7 million 2.6 million
2023-09-30 -20.3 million 3.2 million
2023-06-30 -13.6 million 3.2 million
2023-03-31 -22.4 million 3.7 million

ALGS Net Income

No data available :(

ALGS Cash and Debt

Graph available only for supporters. Become a supporter to see it.
DateCashDebtCapital Lease
2023-12-31 135.8 million - 11.1 million
2023-09-30 70.4 million - 11.8 million
2023-06-30 90.8 million - 12.4 million
2023-03-31 103.5 million - 12.0 million

ALGS Shares Outstanding

Graph available only for supporters. Become a supporter to see it.
DateShares Outstanding
2023-12-31 12.7 million
2023-09-30 43.5 million
2023-06-30 43.2 million
2023-03-31 42.9 million

ALGS Expenses

Graph available only for supporters. Become a supporter to see it.
DateCapexR&DG&AS&M
2023-12-31 7000 22.3 million 6.4 million 775000
2023-09-30 12000 15.9 million 6.4 million -
2023-06-30 7000 16.8 million 9.2 million -
2023-03-31 7000 18.1 million 8.5 million -

ALGS Cost of Revenue

Graph available only for supporters. Become a supporter to see it.
DateRevenueCost of Revenue
2023-12-31 2.7 million 775000
2023-09-30 3.2 million 681000
2023-06-30 6.9 million 769000
2023-03-31 2.7 million 844000

ALGS

Price: $0.80

52 week price:
0.54
1.38

Earnings Per Share: -1.36 USD

P/E Ratio: -0.38

Exchange: NCM

Sector: Healthcare

Industry: Biotechnology

Volume: 78576

Market Capitalization: 81.0 million

Links: